CANCERS BRONCHIQUES NON A PETITES CELLULES NON METASTATIQUES NON RESECABLES |
|
|
référence |
RT thoracique |
chimiothérapie |
n |
survie médiane |
survie à 2 ans |
p |
|
Schaake-Koning, 1992
(1) |
30 Gy/10 x + |
I.
- |
108 |
|
13 % |
|
|
II. CDDP (30 mg/m2/sem) |
98 |
|
19 % |
|||
|
III.
CDDP (6 mg/m2/j) |
102 |
|
26 % |
|||
|
Trovo, 1992
(2) |
45
Gy/15x |
I. - |
88 |
10,3 mo |
|
|
|
II.
CDDP (6 mg/m2/j) |
85 |
10,0 mo |
|
|||
|
Blanke, 1993
(3) |
60-65
Gy |
I. - |
111 |
46 sem |
13 % |
|
|
II. CDDP (70 mg/m2/3 sem) |
104 |
43 sem |
18 % |
|||
|
Jeremic, 1995 (4) |
64,8
Gy (bifractionné) |
I. - |
61 |
8 mo |
25 % |
|
|
II.
1x/sem CBDCA (100 mg j1,2) + VP 16 (100 mg d1,2,3) |
52 |
18 mo |
35 % |
0,002 |
||
|
III. 1x/2sem CBDCA (20 mg j1,2) +
VP16 (100 mg d1-5) |
56 |
13 mo |
27 % |
NS |
||
|
Jeremic, 1996 (5) |
69,6
Gy |
I. - |
65 |
14 mo |
26 % |
|
|
II. CBDCA (50 mg/j) + VP16 (50 mg/j) |
65 |
21 mo |
43 % |
|||
|
Bonner, 1998 (6) |
60
Gy |
I. - |
33 |
|
|
NS |
|
II. CDDP(30x3)- VP16(100x3) x 2 |
32 |
|
|
|||
|
Ball, 1999 (7) |
60
Gy 1x/j |
I. - |
53 |
|
|
NS |
|
II. Carbo (70 j1-5) |
54 |
|
|
|||
|
60
Gy 2x/j |
III
- |
46 |
|
|
||
|
IV. Carbo (70 j1-5) |
51 |
|
|
|||
|
Clamon, 1999 (8) |
60
Gy J50 après 2 cures induction par CDDP-VBL |
I. – |
120 |
13 mo |
|
NS |
|
II. Carbo 100 mg/m² hebdomadaire |
130 |
13 mo |
|
|||
|
Groen, 2004 (9) |
60
Gy (2 Gy/j 5x/sem) |
I. - |
78 |
11,7
mo |
28 % |
NS |
|
II.
Carboplatine 20 mg/m²/j iv continu |
82 |
11,8
mo |
20
% |
|||
|
Cakir, 2004 (10) |
64
Gy (2 Gy/j 5x/sem) |
I.
- |
88 |
|
2%
(3 ans) |
0,0002 |
|
II. CDDP (20 J1-5) |
88 |
|
10 %
(3 ans) |
|||
|
Scagliotti (11) |
60 Gy (2 Gy/j ; 5x/sem) après 2 cycles
de cisplatine + docétaxel |
I. - |
46 |
14 m |
|
NS |
|
II. Docétaxel 20 mg/m²
1x/sem |
43 |
14.9
m |
|
|||
|
Ataqi (12) |
60
Gy !
> 70 ans |
I. 30 mg/m²/j de RT |
100 |
|
|
0,0179 |
|
II. - |
100 |
|
|
Références
(1) Schaake-Koning C, van den Bogaert W, Dalesio O, Festen J, Hoogenhout J, van Houtte P et al. Effects of concomitant cisplatin and radiotherapy on inoperable non- small-cell lung cancer. N Engl J Med 1992; 326(8):524-530.
(2) Trovo MG, Minatel E, Franchin G, Boccieri MG, Nascimben O, Bolzicco G et al. Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non- small cell lung cancer. Int J Radiat Oncol Biol Phys 1992; 24(1):11-15.
(3) Blanke C, Ansari R, Mantravadi R, Gonin R, Tokars R, Fisher W et al. Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small-cell lung cancer: a Hoosier Oncology Group protocol. J Clin Oncol 1995; 13(6):1425-1429.
(4) Jeremic B, Shibamoto Y, Acimovic L, Djuric L. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol 1995; 13(2):452-458.
(5) Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study. J Clin Oncol 1996; 14(4):1065-1070.
(6) Bonner JA, McGinnis WL, Stella PJ, Marschke RFJ, Sloan JA, Shaw EG et al. The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced nonsmall cell lung carcinoma: results of a North Central Cancer Treatment Group Phase III Study. Cancer 1998; 82(6):1037-1048.
(7) Ball D, Bishop J, Smith J, O'Brien P, Davis S, Ryan G et al. A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non- small cell lung cancer: final report of an Australian multi-centre trial. Radiother Oncol 1999; 52(2):129-136.
(8) Clamon G, Herndon J, Cooper R, Chang AY, Rosenman J, Green MR. Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol 1999; 17(1):4-11.
(9) Groen HJ, Van Der Leest AH, Fokkema E, Timmer PR, Nossent GD, Smit WJ et al. Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: a multicenter phase III study. Ann Oncol 2004; 15(3):427-432.
(10) Cakir S, Egehan I. A randomised clinical trial of radiotherapy plus cisplatin versus radiotherapy alone in stage III non-small cell lung cancer. Lung Cancer 2004; 43(309):318.
(11) Scagliotti GV, Szczesna A, Ramlau R, Cardenal F, Mattson K, Van ZN et al. Docetaxel-based induction therapy prior to radiotherapy with or without docetaxel for non-small-cell lung cancer. Br J Cancer 2006; 94(10):1375-1382.
(12) Atagi S, Kawahara M, Yokoyama A, Okamoto H, Yamamoto N, Ohe Y, et al. Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). Lancet Oncol 2012 Jul;13(7):671-8.